Intravenous Hydromorphone for the Treatment of Acute Pain

Launched by THE AFFILIATED NANJING DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL · Apr 21, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called hydromorphone to help relieve acute chest pain. Researchers want to see how effective and safe hydromorphone is for patients experiencing severe chest pain and whether it could be a better option for pain relief in these situations. The goal is to gather information that can help doctors provide more personalized care for patients with acute chest pain, leading to quicker recovery.

To participate in this trial, individuals must be between 18 and 64 years old and have recently experienced severe chest pain that requires strong pain relief. It's important that the pain started within the last 24 days. However, certain people, such as those with specific allergies, low blood pressure, or ongoing chronic pain, may not be eligible. If you join the study, you will receive hydromorphone intravenously, and the care team will monitor your response to the treatment closely. Your safety and comfort are the top priorities throughout the trial.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • 1. Age 18-64 years old;
• • 2. Gender is not limited;
• • 3. Patients with acute chest pain, with the time from pain onset to visit the doctor ≤ 24 days;
• • 4. Severe pain that requires the use of opioids to control as determined by emergency physicians;
• • 5. Obtain informed consent from the patient or family members.
• Exclusion criteria:
• • 1. Known allergy to hydromorphone or morphine;
• • 2. Systolic blood pressure \<100 mmHg, oxygen saturation \<95%, pulse less than 60 beats/min;
• • 3. Use of acetaminophen or nonsteroidal anti-inflammatory drugs in the past 8 hours;
• • 4. Chronic pain, defined as pain lasting for more than 12 weeks;
• • 5. Delirium, alcohol withdrawal symptoms or other drug intoxication;
• • 6. Pregnant or lactating women;
• • 7. Patients with mental or neurological diseases, cognitive and consciousness disorders and inability to express correctly;
• • 8. Participating in any other research at the same time;
• • 9. Factors that increase the risk of participating in the study (life-threatening chest pain patients who require rapid diagnosis or treatment intervention, such as resuscitation status, excluding chest pain caused by myocardial infarction), who are judged by the researchers to be unsuitable for inclusion in the study.